Novo’s ‘Wigobee Feel’ U.S. prescription surpasses 17.6 million casesLily ‘Fighting’ 5 times more than ‘Fighting’The next generation of ‘Genagulated’ is also approved in Korea
Novo Nordisk, which gave Eli Lilly the lead in the global obesity treatment market centered on injections, has launched a strong counterattack
After dominating the oral (eating) obesity treatment market early with increased convenience in medication, it is seeking to regain the throne by entering phase 3 clinical trials of next-generation new drugs that have dramatically increased their weight loss effects
According to the pharmaceutical bio industry on the 28th, the number of weekly prescriptions for Novo Nordisk’s oral obesity treatment “Wigobi Pill” in the U.S. market recently exceeded 176,000
This is an overwhelming gap of about five times compared to competitor Eli Lilly’s oral treatment “Found You” (36,620 cases)
In the existing subcutaneous injection market, Lily’s “Munzaro” surpassed Novo’s “Wigobi” and gained a market share advantage, but in the drug market, Novo Nordisk, which has advanced its release date, is said to have firmly taken the initial lead
Novo Nordisk has also ignited the pace of next-generation pipeline development at the same time as it dominated the oral drug market. Recently, the Ministry of Food and Drug Safety approved the domestic phase 3 clinical trial plan for Novo Nordisk’s next-generation dual-acting obesity treatment candidate ‘Xenagated’ (AMAZE 13)
According to this approval, late-stage clinical trials will be conducted in earnest at major large hospitals such as Seoul National University Hospital and Severance Hospital to evaluate the effectiveness and safety of Asian overweight and obese patients
Genagatide is a peptide double agent that simultaneously targets glucagon-like peptide-1 (GLP-1), which suppresses appetite, and amylin receptors that increase satiety
The results of the previous phase 2 clinical trial are encouraging. In a clinical trial of type 2 diabetes patients, we recorded a weight loss effect of 14.6% in 36 weeks
Considering that diabetic patients usually lose less weight than non-diabetic patients in the medical world, it has proven its potential as a game changer that will strongly threaten Lily, who is currently leading the market in terms of speed and effectiveness
As Novo Nordisk speeds up its two-track strategy of expanding the market through oral treatments and commercializing next-generation injections, the competition for global obesity treatment between the two companies is expected to intensify
An official from a pharmaceutical bio industry predicted, “Oral treatments are a key weapon that can expand the size of the obesity drug market by absorbing new patients who have resistance to injections. If Novo Nordisk takes the initial lead in the drug market and successfully commercializes Genagated, which has significantly increased the speed of its weight loss, the market, which was leaning toward Lily, will fluctuate once again.”
